Nextkidney Enters Phase 2 of Its Clinical Trial Program
February 12, 2026 - Author : Gaëtan Pannetier
Nextkidney is proud to share a major milestone in our journey: we are entering Phase 2 of our clinical trial program for Neokidney.
Following completion of Phase 1, which was designed to evaluate safety of the post-2024 FIH design improvements, this new phase represents an important step forward in building the clinical evidence required to support our mission: improving the dialysis experience and outcomes for patients, while helping care teams deliver high-quality treatment in a more sustainable way.
Why Phase 2 matters
Dialysis is a demanding therapy, both physically and emotionally. For patients, it can shape daily life, energy levels, and overall well-being. For healthcare professionals, it requires constant attention to safety, treatment quality, patient comfort, and operational constraints.
Phase 2 is designed to help us expand our clinical learnings and further evaluate our approach in a structured, rigorous way. It will contribute to generating stronger evidence on performance, safety, and both patient and clinical experience, aligned with the expectations of clinical research and future regulatory pathways.
Clinical progress is a collective effort
Clinical research doesn’t advance because of technology alone. It moves forward thanks to the commitment of patients and healthcare professionals who volunteer their time, attention, and trust to take part in the process.
We want to acknowledge the commitment of :
- Patients who participate and share their experience
- Clinicians and nurses who contribute their expertise and feedback
- Research teams and study coordinators who ensure quality, compliance, and rigor
- Partner sites supporting the study and its operational execution
Their participation to our project is essential. It helps challenge the statu quo and accelerates progress for the entire kidney care community.
A word from our leadership
CEO, Jérôme Augustin:
“Entering Phase 2 is a meaningful step for Nextkidney and for everyone working to improve kidney care. We are grateful to the patients and clinical teams who make this progress possible. Their dedication helps us generate the evidence needed to move innovation forward responsibly, with a clear focus on real-world impact.”
What’s next
As Phase 2 progresses, Nextkidney will share updates when appropriate, ensuring to preserve statistical integrity and adhering to clinical research best practices, partner agreements, and regulatory requirements.
We are thankful to everyone supporting this work and remain committed to advancing solutions that improve both the experience of dialysis and the quality of life of patients and the professionals who care for them.
To follow our journey and future milestones, connect with Nextkidney on LinkedIn.
Neokidney is currently an investigational device and not approved for commercial use.